Tca Cellular Therapy
Biotechnology, New Orleans, Louisiana, 70433, United States, 1-10 Employees
Who is TCA CELLULAR THERAPY
TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatment...
Read More
-
Headquarters: New Orleans, Louisiana, 70433, United States
-
Date Founded: 2004
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 8733
Does something look wrong? Fix it. | View contact records from TCA CELLULAR THERAPY
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding TCA Cellular Therapy
Answer: TCA Cellular Therapy's headquarters are located at New Orleans, Louisiana, 70433, United States
Answer: TCA Cellular Therapy's official website is https://tcacellulartherapy.com
Answer: TCA Cellular Therapy's revenue is $1 Million to $5 Million
Answer: TCA Cellular Therapy's SIC: 8733
Answer: TCA Cellular Therapy has 1-10 employees
Answer: TCA Cellular Therapy is in Biotechnology
Answer: TCA Cellular Therapy contact info: Phone number: Website: https://tcacellulartherapy.com
Answer: TCA Cellular Therapy, LLC (TCA-CT) is a privately-held biotherapeutics company whose mission is to create and accelerate adult stem cell therapies and to develop next generation treatments for serious and life-threatening diseases. The company utilizes single or a combination of autologous (patients own) adult stem cells to treat various diseases, related to the cardiovascular, nervous, skeletal and muscular systems. Six FDA-approved clinical trials at Phases I, II and/or II/III are underway to treat Heart Disease, Peripheral Vascular Disease (PVD), Peripheral Arterial Disease (PAD), Limb Ischemia, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrigs disease) and Spinal Cord Injuries. TCA-CTs adult stem cell research allows us to produce a marketable biological product to regenerate damaged blood vessels and organs. As soon as Phase III studies are completed and approved by the FDA for the United States market, the adult stem cell products developed by TCA-CT will be transplanted into humans as treatments for a variety of diseases.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month